{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:23:22Z","timestamp":1790011402014,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.athplu.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T13:32:46Z","timestamp":1633354366000},"page":"32-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5992-9357","authenticated-orcid":false,"given":"Marina","family":"Blanco-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Amaya-Pascasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-9460","authenticated-orcid":false,"given":"Reyes","family":"de Torres Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Josefa","family":"\u00c1lvarez Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Arjona-Padillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Magdalena","family":"Carrillo Bail\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Mil\u00e1n Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"P\u00e9rez Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"S\u00e1nchez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Andrade Zum\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Valverde Moyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pay\u00e1n Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Mar\u00eda","family":"Castillo Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Del Toro P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-1308","authenticated-orcid":false,"given":"Pablo","family":"Gonz\u00e1lez Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ag\u00fcera Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purificaci\u00f3n","family":"S\u00e1nchez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Hidalgo Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2043-7173","authenticated-orcid":false,"given":"Ricardo","family":"Roa Chamorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fern\u00e1ndez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Mej\u00edas Olmedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-4435","authenticated-orcid":false,"given":"Patricia","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.athplu.2021.08.009_bib1","first-page":"e596","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.athplu.2021.08.009_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.athplu.2021.08.009_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2021.08.009_bib4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","article-title":"Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction","volume":"27","author":"Gislason","year":"2006","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.athplu.2021.08.009_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and management of statin intolerance","volume":"26","author":"Alonso","year":"2019","journal-title":"J\u00a0Atherosclerosis Thromb"},{"issue":"S1","key":"10.1016\/j.athplu.2021.08.009_bib6","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3909\/ricm19S1S0005","article-title":"Statin intolerance","volume":"19","author":"Brown","year":"2018","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.athplu.2021.08.009_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00228-015-1994-9","article-title":"Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies","volume":"72","author":"Trompet","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.athplu.2021.08.009_bib8","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2021.08.009_bib9","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2021.08.009_bib10","doi-asserted-by":"crossref","first-page":"Suppl","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J\u00a0Lipid Res"},{"issue":"16","key":"10.1016\/j.athplu.2021.08.009_bib11","first-page":"155","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"163","author":"Sabatine","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.athplu.2021.08.009_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"issue":"16","key":"10.1016\/j.athplu.2021.08.009_bib13","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2021.08.009_bib14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2021.08.009_bib15","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"LAPLACE-2 Investigators, Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.athplu.2021.08.009_bib16","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"GAUSS-2 Investigators, Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2021.08.009_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.athplu.2021.08.009_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A\u00a052-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2021.08.009_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"10.1016\/j.athplu.2021.08.009_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.athplu.2021.08.009_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40801-019-00166-7","article-title":"A\u00a0retrospective observational study to determine baseline characteristics and early prescribing patterns for patients receiving alirocumab in UK clinical practice","volume":"64","author":"Reynolds","year":"2019","journal-title":"Drugs - Real World Outcomes"},{"key":"10.1016\/j.athplu.2021.08.009_bib22","author":"Sarsam"},{"key":"10.1016\/j.athplu.2021.08.009_bib23","first-page":"1","article-title":"PCSK-9 inhibitors in a real-World setting and a comparison between alirocumab and evolocumab in heterozygous FH patients","volume":"5","author":"Ceballos-Mac\u00edas","year":"2021","journal-title":"J.\u00a0Endocr. Soc."},{"key":"10.1016\/j.athplu.2021.08.009_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1253\/circrep.CR-19-0027","volume":"1","author":"Yokote","year":"2019","journal-title":"Circ. Reports"},{"key":"10.1016\/j.athplu.2021.08.009_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5603\/CJ.a2017.0137","article-title":"Lipid-lowering therapy with pcsk9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world cohort","volume":"25","author":"Saborowski","year":"2018","journal-title":"Cardiol J"},{"key":"10.1016\/j.athplu.2021.08.009_bib26","series-title":"Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom","first-page":"829","author":"Tai","year":"2018"},{"issue":"21","key":"10.1016\/j.athplu.2021.08.009_bib27","first-page":"83","article-title":"PCSK9 inhibitors in a German single-center clinical practice: real-World treatment of patients at high cardiovascular risk over 68 weeks","volume":"211","author":"Hollstein","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.athplu.2021.08.009_bib28","unstructured":"Informe de Posicionamiento Terap\u00e9utico de Evolocumab (Repatha \u00ae ) En hipercolesterolemia, (n.d.)."},{"key":"10.1016\/j.athplu.2021.08.009_bib30","series-title":"Evinacumab in patients with refractory hypercholesterolemia","first-page":"2307","author":"Rosenson","year":"2020"},{"issue":"2","key":"10.1016\/j.athplu.2021.08.009_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40261-019-00877-3","article-title":"PCSK9 Inhibitors' new users: analysis of prescription patterns and patients' characteristics from an Italian real-world study","volume":"40","author":"Piccinni","year":"2020","journal-title":"Clin Drug Invest"},{"issue":"5","key":"10.1016\/j.athplu.2021.08.009_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12439","article-title":"Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: two-year experience of a regional lipid clinic","volume":"36","author":"Zafrir","year":"2018","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"10.1016\/j.athplu.2021.08.009_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40256-017-0246-z","article-title":"Patient characteristics and real-world treatment patterns among early users of PCSK9 inhibitors","volume":"18","author":"Rane","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"10.1016\/j.athplu.2021.08.009_bib34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.athplu.2021.08.009_bib35","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.numecd.2020.06.028","article-title":"Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: a retrospective, single center, observational study","volume":"30","author":"D'Erasmo","year":"2020","journal-title":"Nutr Metabol Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.athplu.2021.08.009_bib36","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.clinthera.2021.02.002","article-title":"Effectiveness, safety, and adherence to treatment of proprotein convertase subtilisin\/Kexin type 9 inhibitors in real practice","volume":"43","author":"Gayoso-Rey","year":"2021","journal-title":"Clin Therapeut"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089521000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089521000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:43:41Z","timestamp":1763023421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089521000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":35,"alternative-id":["S2667089521000419"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2021.08.009","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}